Blanc, E.
Chaize, G.
Fievez, S.
Féger, C.
Herquelot, E.
Vainchtock, A.
Timsit, J. F.
Gaillat, J.
Funding for this research was provided by:
Pfizer France
Article History
Received: 15 December 2020
Accepted: 28 August 2021
First Online: 14 September 2021
Declarations
:
: This study was conducted in full compliance with relevant guidelines and regulations. This study is conducted using anonymized data extracted from an existing database; thus, according to French regulations, there is no need for an informed consent from patients nor for an approval of an Ethic committee.
: Not applicable.
: EB and SF are employees of Pfizer France; GC, EH and AV are employees of HEVA, contracted by Pfizer France to conduct the statistical analysis; CF is CEO of EMIBiotech, contracted by Pfizer to contribute to coordinate the study results discussion and the draft of the manuscript; JFT received fees for advisory boards of Astellas, Bayer, Beckton-Dickinson, Gilead, Medimune, Merck, Nabriva, Paratek, Pfizer. The research group of JFT received grants from 3 M, Merck, Pfizer, JFT is the principal investigator of one RCT of community acquired pneumonia sponsored by the French ministry of health (MULTICAP; PHRCN-16-0595; ClinicalTrials.gov Identifier: NCT03452826); JG is member of advisory boards and gave lectures for Pfizer, Sanofi and MSD.